Skip to main content

Robert Martin

All Speakers

Robert Martin

Real-World Regulated Access vs. Clinical Trials: Supplying Both from One GMP Psilocybin & MDMA Facility
Robert Martin is Chief Strategy Officer of Optimi Health Corp. (Nasdaq: OPTH), a commercial-stage Canadian manufacturer of GMP finished-dose natural psilocybin and MDMA. A growth investor with 20+ years of experience, he leads Optimi’s strategy and international expansion, including commercial supply to Australia’s Authorised Prescriber Scheme and UK Phase 2 clinical trials.
How Optimi Health standardized natural psilocybin into GMP finished-dose capsules at its Health Canada-licensed facility and supplies regulated-access markets and clinical trials from one site: Australian Authorised Prescriber exports for TRD/PTSD, UK Phase 2 supply, reimbursement pathways, and real-world safety data from a 750+ clinician network.
Skip to content